E-Briefings

Research now links human saliva proteins in a multitude of ways. With saliva signatures recognized by thousands of identifiable proteins, a new public database that catalogs and curates this data in relation to disease studies offers a promising resource for hospitals.

With a new Kidney Care Choices model starting January 1, 2022, hospital executives may be considering strategies, including precision medicine strategies.

A new 3D bio-printing method marks an exciting beginning to precision medicine treatments for highly-aggressive glioblastoma cancer.

Breast imagers are uniquely positioned to lead the way in AI cancer screening through their extensive experience with computer-assisted diagnosis (CAD), stated Constance Lehman, MD, PhD, a diagnostic radiologist, Professor of Radiology at Harvard Medical School, and Director of Breast Imaging at MGH.

Research will continue toward the value and medical necessity of both WES and WGS where results directly influence medical management and clinical outcomes. As a result, reimbursement for the uses of these testing methods may be changing as more about their roles is learned.

New research from Aarhus University, recently published in Translational Psychiatry, analyzed the frequency of genetic variations that affect drug metabolism and drug targets in over 77,000 patients. What the study found.

“With these new reference data, genetic differences can be studied with unprecedented accuracy against the background of global genetic variation, which facilitates the biomedical evaluation of genetic variants carried by an individual,” said co-first author, Peter Ebert, PhD, a bioinformatics software engineer at the Institute for Medical Biometry and Bioinformatics at Heinrich Heine University.

The new collaboration between Epic and Foundation Medicine integrates Foundation’s comprehensive genomic profiling (CGP) and other testing services with Epic’s electronic medical record (EMR) system. Genomic information will power clinical decision support.

Because of the increased number of risk adjustment programs, improved diagnosis and treatment of chronic kidney disease (CKD) could trigger substantial financial benefit. This research maps a path for physicians and health systems to better utilize existing medications for their patients with CKD.

Statement comes at a time of recent draft legislation and “bipartisan support” for the creation of a new advanced research agency to cure cancer and currents of a “highly anticipated” 21st Century Cures 2.0 bill.